Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro

Journal of Bone and Mineral Research

Volumn 28, Issue 1, 2013, Pages 35-45

  Xiao, Liping ^a   Esliger, Alycia ^a   Hurley, Marja M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

FGF RECEPTOR INHIBITOR; FGF23; HMWFGF2; MAPK; PHOSPHATE

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; ISOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; OSTEOCALCIN; PHOSPHATE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ARTICLE; BONE MARROW STROMAL CELL; BONE MINERALIZATION; CELL CULTURE; CONTROLLED STUDY; IN VITRO STUDY; MALE; MODULATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; PHOSPHATE METABOLISM; SIGNAL TRANSDUCTION; STROMA CELL;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; CELL NUCLEUS; CULTURE MEDIA, CONDITIONED; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; FLAVONOIDS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; NEUTRALIZATION TESTS; OSTEOCALCIN; OSTEOGENESIS; PHOSPHORYLATION; PROTEIN ISOFORMS; PYRROLES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, MESSENGER; TIME FACTORS;

EID: 84872874858     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1721     Document Type: Article

References (36)

1. Globus RK, Plouet J, Gospodarowicz D,. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. Endocrinology. 1989; 124 (3): 1539-47.
2. Florkiewicz RZ, Sommer A,. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci U S A. 1989; 86 (11): 3978-81.
3. Arese M, Chen Y, Florkiewicz RZ, Gualandris A, Shen B, Rifkin DB,. Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol Biol Cell. 1999; 10 (5): 1429-44.
4. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn GW 2nd, Lightfoot P, German R, Howles PN, Kier A, O'Toole BA,. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell. 1995; 6 (12): 1861-73.
5. Sobue T, Naganawa T, Xiao L, Okada Y, Tanaka Y, Ito M, Okimoto N, Nakamura T, Coffin JD, Hurley MM,. Over-expression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. J Cell Biochem. 2005; 95 (1): 83-94.
6. Xiao L, Liu P, Li X, Doetschman T, Coffin JD, Drissi H, Hurley MM,. Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. J Biol Chem. 2009; 284 (5): 3170-82.
7. Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD, Hurley MM,. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J Biol Chem. 2010; 285 (4): 2834-46.
8. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB,. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004; 145 (7): 3087-94.
9. Eicher EM, Southard JL, Scriver CR, Glorieux FH,. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A. 1976; 73 (12): 4667-71.
10. Lu Y, Feng JQ,. FGF23 in skeletal modeling and remodeling. Curr Osteoporos Rep. 2011; 9 (2): 103-8.
11. Xiao L, Sobue T, Esliger A, Kronenberg MS, Coffin JD, Doetschman T, Hurley MM,. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone. 2010; 47 (2): 360-70.
12. Sheehan DC, Hrapchak BB,. Theory and practice of histotechnology. 2nd ed. Chicago: Year Book Medical Publishers; 1980. 481 p.
13. Keila S, Pitaru S, Grosskopf A, Weinreb M,. Bone marrow from mechanically unloaded rat bones expresses reduced osteogenic capacity in vitro. J Bone Miner Res. 1994; 9 (3): 321-7.
14. Gregory CA, Gunn WG, Peister A, Prockop DJ,. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem. 2004; 329 (1): 77-84.
15. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29 (9): e45.
16. Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N,. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008; 23 (6): 939-48.
17. Stachowiak MK, Fang X, Myers JM, Dunham SM, Berezney R, Maher PA, Stachowiak EK,. Integrative nuclear FGFR1 signaling (INFS) as a part of a universal "feed-forward-and-gate" signaling module that controls cell growth and differentiation. J Cell Biochem. 2003; 90 (4): 662-91.
18. Dunham-Ems SM, Lee YW, Stachowiak EK, Pudavar H, Claus P, Prasad PN, Stachowiak MK,. Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. Mol Biol Cell. 2009; 20 (9): 2401-12.
19. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M,. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996; 271 (25): 15292-7.
20. Yu X, White KE,. Fibroblast growth factor 23 and its receptors. Ther Apher Dial. 2005; 9 (4): 308-12.
21. Fukumoto S,. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism]. Rinsho Byori. 2007; 55 (6): 555-9. [Japanese].
22. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J,. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117 (12): 4003-8.
23. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N,. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem. 2002; 277 (31): 28265-70.
24. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M,. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281 (10): 6120-3.
25. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T,. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444 (7120): 770-4.
26. Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, Hawkins N, Richards WG,. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int. 2011; 89 (2): 140-50.
27. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI,. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390 (6655): 45-51.
28. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B,. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002; 108 (1): 17-29.
29. Nishio Y, Dong Y, Paris M, O'Keefe RJ, Schwarz EM, Drissi H,. Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. Gene. 2006; 372: 62-70.
30. Pregizer S, Baniwal SK, Yan X, Borok Z, Frenkel B,. Progressive recruitment of Runx2 to genomic targets despite decreasing expression during osteoblast differentiation. J Cell Biochem. 2008; 105 (4): 965-70.
31. Gopalakrishnan R, Suttamanatwong S, Carlson AE, Franceschi RT,. Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization. Cells Tissues Organs. 2005; 181 (3-4): 166-75.
32. Xiao L, Liu P, Sobue T, Lichtler A, Coffin JD, Hurley MM,. Effect of overexpressing fibroblast growth factor 2 protein isoforms in osteoblastic ROS 17/2.8 cells. J Cell Biochem. 2003; 89 (6): 1291-301.
33. Liu S, Tang W, Fang J, Ren J, Li H, Xiao Z, Quarles LD,. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol. 2009; 23 (9): 1505-18.
34. Kyono A, Avishai N, Ouyang Z, Landreth GE, Murakami S,. FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation. J Bone Miner Metab. 2012 Jan; 30 (1): 19-30.
35. Peng H, Myers J, Fang X, Stachowiak EK, Maher PA, Martins GG, Popescu G, Berezney R, Stachowiak MK,. Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C. J Neurochem. 2002; 81 (3): 506-24.
36. Hoang QQ, Sicheri F, Howard AJ, Yang DS,. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature. 2003; 425 (6961): 977-80.